News

Under a research agreement signed between the two parties, JDRF is responsible to give milestone-based financial help to Selecta with an aim to use Selecta’s technology for the

Currently, the company is evaluating the safety, tolerability and immunogenicity of NuThrax also known as AV7909, which is in a Phase 1b trial. According to the company, the

The 12 weeks data showed positive results demonstrating an increase in ‘on’ time and decrease in ‘off’ time without troublesome dyskinesias. Abbott said the primary efficacy endpoint is

Daliresp is a selective PDE4 inhibitor, indicated as a treatment for reducing the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with

Validus pharmaceutical had been using a CRM system that ran on PDAs and could not report on all sales activity data. The screens on the PDA devices previously

The company is currently reviewing IRB’s request and expects to submit a revised Phase 2 clinical trial protocol to the board later this month. AVI BioPharma president and

Amylin recently filed litigation involving the two companies’ diabetes collaboration agreement. Lilly senior vice president and general counsel Robert Armitage said they have complied with their contractual obligations

Matrix M is an immune stimulating substance for use in vaccines, antibody production and immunological research. Matrix M was already licensed to Crucell for use in influenza vaccines,

The changes to the label for simvastatin-containing medications are based on the FDA’s review of the results of the seven-year Study of the Effectiveness of Additional Reductions in